Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sherif El-Refai"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/8cabee68d6f64665a36c6aed98e5d3bb
Publikováno v:
Cancer Research. 83:P2-23
Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients. These mutations cluster in the kinase domains and at amino acids 309-310 in the extracellular domain. The MutHER, SUMMIT, and PlasmaMATCH clinical trials
Autor:
Cameron Czech, Ashley Chen, Katherine P. Morgan, Carlos Zamora, Sherif El-Refai, Norleena Poynter, Simon Khagi
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(9)
Glioblastoma (GBM) is a malignant central nervous system neoplasm that remains largely incurable. Limited treatment options currently exist after disease progression on standard-of-care first-line therapy. However, repurposing the use of approved the
Autor:
Mark Yarchoan, Daniel J. Zabransky, Kabir Mody, Elizabeth M. Jaffee, Prerna Jain, Sherif El-Refai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCholangiocarcinoma (CCA) is an aggressive malignancy of the biliary tract that carries an unfavorable prognosis. Recurrent, hotspot mutations in the IDH1 gene are found in 10–20% of CCAs and can be targeted with mutant IDH1 inhibitors, th
Autor:
Axel Grothey, Wei Sha, Mohamed E. Salem, J. Tabernero, Alberto Puccini, Thomas J. George, E. Van Cutsem, Kunal C. Kadakia, Jimmy J. Hwang, Sherif El-Refai, Jeanne Tie, Laura W. Musselwhite
Publikováno v:
Annals of Oncology. 32:S218
Autor:
Axel Grothey, Kunal C. Kadakia, Thomas J. George, Josep Tabernero, Mohamed E. Salem, Laura W. Musselwhite, Eric Van Cutsem, Jeanne Tie, Sherif El-Refai, Jimmy J. Hwang, David J. King, Alberto Puccini, Wei Sha, Derek Raghavan
Publikováno v:
Journal of Clinical Oncology. 39:3127-3127
3127 Background: Sotorasib has shown promising activity in cancer patients (pts) specifically harboring the KRASG12C mutation. Response rates vary significantly by tumor type, suggesting KRASG12C pathogenesis may be cancer-type-dependent. Methods: We
Autor:
Gregory B. Lesinski, Kabir Mody, Denise Lau, Anthony B. El-Khoueiry, Nilofer S. Azad, Rachna T. Shroff, Mark Yarchoan, Prerna Jain, Robin Kate Kelley, Sherif El-Refai
Publikováno v:
Journal of Clinical Oncology. 39:4023-4023
4023 Background: Biliary tract cancers (BTC) are increasingly subtyped by molecular alterations, but little is known about the relationship between gain-of-function mutations and the RNA transcript expression of immune-related pathways. Methods: A sa
Autor:
David J. King, Alberto Puccini, Carol J. Farhangfar, James T. Symanowski, Sherif El-Refai, Mohamed E. Salem, Hsih-Te Yang, Edward S. Kim
Publikováno v:
Journal of Clinical Oncology. 39:104-104
104 Background: Molecular changes and associated acquired resistance of rectal tumors following chemoradiotherapy (CRT) have not been well studied. We aimed to examine CRT-induced molecular changes and prognostic associations in rectal cancer patient
Autor:
Sherif El-Refai, Mohamed E. Salem
Publikováno v:
Rare Cancers and Therapy. 1:3-19
Vascular endothelial growth factor (VEGF) and related pathway elements are critically important in the pathogenesis, growth, and development of solid tumors. Inhibiting the VEGF signaling pathway is being investigated as a therapeutic strategy for ca
Autor:
Mohamed E. Salem, Nitin Jain, Stephanie Taylor, Gregory Dyson, Philip A. Philip, Minsig Choi, Jeffery Critchfield, Sherif El-Refai, Anthony F. Shields
Publikováno v:
ISRN Oncology
Background. In patients with hepatocellular carcinoma, selection criteria for transarterial hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters to predict outcome of transarterial hepatic selective internal ra